Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers. 

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers

Mitazalimab combined with mFOLFIRINOX led to responses and survival benefits in patients with metastatic pancreatic ductal adenocarcinoma. 

Mitazalimab Plus mFOLFIRINOX Improves Survival in Pancreatic Cancer

The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data. 

Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer

Docetaxel was associated with lower rates of peripheral neuropathy compared with paclitaxel for Black patients with breast cancer. 

Chemo Should be Tailored to Decrease Neuropathy in Black Patients

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Articles

Belantamab Mafodotin Combos Get BLA for Myeloma Treatment

Megan is an assistant editor at MJH. She joined the company in 2022 after graduating from UMass Amherst with majors in communication and english. When not at work, Megan enjoys fishing, spending time with her twin sister, and listening to Taylor Swift on repeat. Email Megan at mhollasch@onclive.com

An expert discusses the FDA approval of obecabtagene autoleucel—the only CAR T-cell therapy given via split dosing for patients with ALL. 

Obe-Cel Approval Was a ‘Major Milestone’ for ALL Treatment

The FDA approved a companion diagnostic to identify patients with biliary tract cancer eligible for treatment with zanidatamab. 

FDA Approves Companion Diagnostic for Zanidatamab in Biliary Tract Cancer

Larotrectinib led to rapid/durable responses and high disease control rates in children with TRK fusion-position central nervous system cancers. 

Larotrectinib Is Promising for Pediatric TRK Fusion-Positive CNS Tumors

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

Authors

Families are communities within themselves-full of intrigue, adventures, worries, joys, and assorted characters. 

"Oh, and by the way..." A Lynch Syndrome Story

The FDA approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test as a companion diagnostic for HER2-positive status in patients with biliary tract cancer. The test will identify patients who are eligible for treatment with zanidatamab-hrii (Ziihera).

the FDA granted accelerated approval to the bispecific antibody zanidatamab

 for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) biliary tract cancer, as detected by an FDA-approved test.

“This test is a step forward in furthering access to personalized medicine,” Jill German, head of the Pathology Lab at Roche Diagnostics, stated in a news release.1 “The prognosis for patients diagnosed with biliary tract cancer is poor, as very few treatment options exist. Now, these patients have access to the first standardized test that could make them eligible for targeted therapy, potentially improving clinical outcomes.”

The FDA approval of zanidatamab was backed by findings from the phase 2b HERIZON-BTC-01 trial (NCT04466891), which enrolled 87 patients with 

-amplified, locally advanced unresectable or metastatic biliary tract cancer, including gallbladder cancer and intra-/extra-hepatic cholangiocarcinoma, who had received prior gemcitabine-containing therapy.2 Patients were excluded if they had received prior HER2-targeted therapy. All patients needed to have centrally confirmed HER2 status on tissue samples.

Patients received intravenous zanidatamab at 20 mg/kg every 2 weeks. Confirmed overall response rate (cORR) by independent central review served as the primary end point. Key secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival, overall survival (OS), and safety.

The data that supported the approval showed that patients with HER2 IHC 3+ biliary tract cancer who received the bispecific antibody (n = 62) achieved an ORR of 52% (95% CI, 39%-65%) and an estimated median DOR of 14.9 months (95% CI, 7.4-not evaluable).

Long-term follow-up data presented at the 

 showed that at a median follow-up of 22 months (range, 16-34) and a data cutoff date of July 28, 2023, the cORR and DCR were maintained from the primary analysis in patients with HER2-positive disease, at 41.3% and 68.8%, respectively.3 One additional patient had achieved a complete response. A preplanned subgroup analysis of cORR by HER2 expression demonstrated cORRs in both the IHC 3+ and IHC 2+ cohorts at 51.6% and 5.6%, respectively.

The median DOR increased to 14.9 months (95% CI, 7.4-not reached) from the primary analysis. The median OS was 15.5 months (95% CI, 10.4-18.5). The median OS in the IHC 3+ and IHC 2+ cohorts was 18.1 months (95% CI, 12.2-23.2) and 5.2 months (3.1-10.2), respectively. The 12-month OS rate was 56.2% (95% CI, 44.3%-66.5%) in the HER2-positive population; this rate was 65.0% (95% CI, 51.6%-75.6%) and 20.8% (95% CI, 5.1%-43.7%) in the IHC 3+ and IHC 2+ cohorts, respectively.

Safety was evaluated in 87 patients in HERIZON-BTC-01. A total of 96.6% of patients had any treatment-emergent adverse effects (AEs); 72.4% of patients had any treatment-related AEs (TRAEs; grade 1/2, 51.7%; grade 3/4, 20.7%). Overall, the most common any-grade TRAEs observed in patients treated with zanidatamab were diarrhea (36.8%), infusion-related reactions (33.3%), decreased injection fraction levels (10.3%), and nausea (9.2%).

Serious TRAEs occurred in 9.2% of patients who received zanidatamab. In total, 2.3% of patients who received zanidatamab permanently discontinued treatment with the agent due to an AE. However, at the long-term follow-up analysis, no patients had discontinued treatment due to a TRAE since the prior analysis. TRAEs leading to dose reductions included grade 3 diarrhea (n = 1), grade 1 diarrhea/grade 1 nausea (n = 1), and grade 2 weight decrease (n = 1).

One patient had a fatal AE of hepatic failure.2 However, no deaths on the trial were attributed to zanidatamab.

The ongoing, confirmatory phase 3 HERIZON-BTC-302 trial (NCT06282575) is evaluating frontline zanidatamab plus standard-of-care (SOC) therapy vs SOC therapy alone in patients with HER2-positive biliary tract cancer.1

1. Roche receives FDA approval for first companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with ZIIHERA. News release. Roche. November 25, 2024. Accessed November 25, 2024. https://www.prnewswire.com/news-releases/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary-tract-cancer-eligible-for-her2-targeted-treatment-with-ziihera-302314548.html

2. Jazz Pharmaceuticals announces U.S. FDA approval of Ziihera® (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC). News release. Jazz Pharmaceuticals. November 20, 2024. Accessed November 25, 2024. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-us-fda-approval-ziiherar

3. Pant S, Fan J, Oh D-Y, et al. Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study. 

. 2024;42(suppl 16):4091. doi:10.1200/JCO.2024.42.16_suppl.4091

Anne M. Reb, PhD, NP, discussing a nurse-led intervention for fear of cancer recurrence.

Shift in Nurse-Led Mindset Helps Quell Fear of Cancer Recurrence 

An intervention focusing on techniques to better focus patients’ attention may be beneficial in improving fear of cancer recurrence, according to recent research presented at the 21st International Conference of the Society for Integrative Oncology.

In a recent interview, study author Anne M. Reb, PhD, NP, discusses her abstract on a nurse-led videoconferencing intervention for patients with advanced cancer who may experience the fear of recurrence. Reb, who is an assistant professor of Nursing Research and Education at City of Hope, Duarte, California, explained that fear of recurrence is common, occurring in up to 70% of patients with advanced cancer.2 However, mindfulness interventions may help.

We teach mindset skills and we teach mindfulness-based skills. So we teach mindset skills to help people manage these thoughts and feelings that become sometimes overwhelming and intrusive, and we help them to know that they have more control over their thoughts than they think they have, because many people feel like they can't control their thoughts. None of us can control our thoughts and our feelings, they’re right.

But you can control where you focus your attention. You can choose how you manage these thoughts. And there's some exercises that you can do that we teach to help you better manage your thoughts. And you know, our thoughts and our feelings and our actions are all closely interrelated. Sometimes, if we have [a lot of] worries, [we may] believe that worry is really going to help us, or, in turn…that worry is harmful, these beliefs and these thoughts that we have influence our behaviors and our actions.

For example, some people might be so worried they feel like they need to worry, because it's going to help them keep on top of any new symptom that they get. They're going to report it to their doctor or to their nurse right away, so that if there is a cancer recurrence, they're going to catch it early. So, they think that worrying is going to protect them in some way.

Some people believe that worry is really harmful, and [they think] “worry is going to make my cancer come back,” or, “I believe that this new ache or pain that I'm having is going to mean that cancer is coming back.” Or they might think that their worries are uncontrollable, and that's a very common thing.

In this program, we teach them skills to think about how they're thinking. Our thought processes are very automatic, and we teach skills to notice your thought patterns, notice what you're believing, notice your actions.

So, for example, one patient, she was on the internet several times a day—up to 10 and 12 times—looking for new cancer trials and treatments. That was helping her to feel more comfortable that if…her cancer did progress, that she would be able to quickly tap into 1 of these new trials.

But I asked, “How's that working for you?” And she said, “Well, it's actually making me a little anxious, because I feel like I'm tired of the computer.” And I so I said, “Is there any way that you can cut back on that a little bit. How would that feel to you?” And she said, “Well, I could give that a try.”

So instead of checking the internet 10 times a day, she would check it in the morning and in the evening, and then that gave her more time to focus on what really was most important to her—spending time on things that she enjoyed, like pickleball and hanging out with her friends. So it really helps you to focus on the skills we teach to help you to really focus your attention with the goal of being able to have improved concentration and focus on the things that matter most to you.

1. Reb AM. A Nurse-Led Videoconferencing Intervention for Fear of Progression in Advanced Cancer: A Pilot Study. Presented at: 21st International Conference of the Society for Integrative Oncology. October 25-27, 2024.

2. Lebel S, Ozakinci G, Humphris G, et al. Current state and future prospects of research on fear of cancer recurrence. 

 Apr;26(4):424-427. doi: 10.1002/pon.4103.

“You can control where you focus your attention,” said Anne M. Reb, PhD, NP, who recently presented on a nurse-led intervention for patients who experience fear of cancer recurrence. 

Onc Nurse TV

Advanced Practice Corner

Shift in Nurse-Led Mindset Helps Quell Fear of Cancer Recurrence

Up to 75% of women being treated for breast cancer report that they have experienced sexual dysfunction; however, there is a lack of patient-provider communication about these issues.

, Michelle Taylor, ANP, discusses the importance of having these discussions about sexual health, and remedies that oncology nurses and advanced practice providers can recommend for patients experiencing these effects.

“The shift comes when you just try [to have these discussions]. Then next time you have the conversation, it’s a little easier,” Taylor, a nurse practitioner for adult patients at Dignity Health Cancer Institute at St. Joseph’s in Phoenix, AZ, said. “Sometimes even if you don’t know what advice to give to that woman, just being heard is something that is often very important.”

: Why is sexual health important in women with breast cancer?

 When you're a breast oncology-specific [health care provider], you have a large population, typically, of women, between the age of 40 and 60, and they're working, they're in relationships. It's just not something that's talked about enough.

I think vaginal health specifically should be talked about more, because whether someone is engaging in intercourse or not, we know that vaginal dryness can be tied to things like more frequent [urinary tract infections], more frequency of urination, and incontinence. These can be pretty debilitating side effects. No, it's not a grade 3 diarrhea that's requiring emergent intervention, but it is a major quality-of-life issue.

Is there a specific type of cancer treatment that affects vaginal and sexual health?

The truth of the matter is, depending on which literature you're looking at, nearly 85% of men and women can experience sexual side effects from any modality of treatment for cancer therapy, including traditional IV chemotherapy, certainly these oral medications and even things like radiation and surgical intervention.

Sexual dysfunction occurs mainly in the breast cancer setting, as we are lowering estrogen levels, even when it's not a direct medication that does this, such as [goserelin acetate [Zoladex]) injections or an aromatase inhibitor. There is ovarian suppression that comes from chemotherapy, for example.

What are common sexual adverse effects from breast cancer treatment, and are there ways to treat them?

So, the first mechanism is typically vaginal dryness, and that can be layering on top of an already existing vaginal dryness. And then [there are] physical effects of stenosis of the vaginal canal, making intercourse uncomfortable, and also just simply the reduction in libido. There’s body dysmorphia that can happen to a woman who has gone through breast surgery, radiation, chemotherapy, so the physical changes that can happen as well.

So there's many layers to sexual health in this setting. And I think that there are ways to help curb some of this. A lot of the women are coming in with those existing symptoms already, and then we're exacerbating them.

Teaching a woman up front, being comfortable yourself, having those uncomfortable conversations once you let a woman know that you're here and willing to talk about really anything that they're experiencing [is important], I think they become more comfortable sharing those things. We tend to recommend proactive moisturization with things as simple as coconut oil, which is very safe for external moisturization, as well as lubrication for intercourse, but there are also products that contain hyaluronic acid that are vaginal moisturization products that are very easy to use overnight.

I can go on and on about this. It's a personal passion of mine, based on what we see our women experience here, but it is something that all oncology nurses should be aware of, no matter what setting they're working in.

Hernández-Blanquisett A, Quintero-Carreño V, Álvarez-Londoño A, et al. Sexual dysfunction as a challenge in treated breast cancer: in-depth analysis and risk assessment to improve individual outcomes. 

A nurse practitioner discusses how breast cancer treatment can impact sexual health, and how nurses and APPs can guide patients through these effects. 

Sexual Health During Breast Cancer: ‘Just Being Heard Is Important’

Heather J. Jackson, PhD, APRN, FNP-BC, NEA-BC, FAANP in an interview with Oncology Nursing News

Tapering treatment with opioids for cancer-related pain can be a challenging process. However, when there is suspected opioid misuse, clinicians should consider faster tapering combined with non-opioid treatments to prevent harm to the patient or others, explained Heather J. Jackson, PhD, APRN, FNP-BC, NEA-BC, FAANP.

Jackson is the administrative director of advanced practice at Vanderbilt-Ingram Cancer Center and associate professor of Nursing and of Medicine in the Division of Hematology/Oncology

Vanderbilt University Medical Center. In a recent interview with 

, she discussed safe opioid tapering and multimodal pain management for patients experiencing cancer-related pain. The process, she explained, may look different in situations of misuse, she said, noting that potential signs of opioid misuse include:

Patients continuing to fill their prescription and request early refills, though no opioids are detected in urine samples (this can indicate that somebody else is taking the patient’s opioids or potential diversion)

Odd interactions with patients or family members regarding opioid use

Patients seeming to plan their daily schedule around taking opioids 

Patients indicating they are withdrawing from typical daily tasks or social activities with impacted relationships

Changes in mood such as irritability, nervousness, or fluctuations in emotions

“In a situation of misuse, we don’t want to put those drugs out there,” Jackson said. “We don’t want to harm the patient; we don’t want to harm other people. So we do have to do a rapid taper and offer alternative pain remedies as well as assess for substance use disorders.”

If we come upon a situation where we do [suspect] misuse, we discuss our concerns with the patient. Often a warning and limited number of opioid medications are prescribed and if misuse is validated, we proceed with a rapid taper. Our goal and our objective would be to be slow about this, and even have pauses in a taper. I've been known to spend a year-and-a-half with a patient that came to me on very high, extended-release regimens, and then with a short-acting [opioid prescription] on top of that…. I’ve had to pause, and they'll say, “it's a rough month … going on. Heather, can we please just pause there?” And absolutely you can do that.

But in a situation of misuse, we can't put those drugs out there. We don't want to harm the patient. We don't want to harm other people. So we do have to do a rapid taper, and in that situation, we'd want to address the symptoms of withdrawal, knowing that they can certainly be uncomfortable, but it's not going to harm the patient medically. We can give medicines to help with those symptoms. So we would want to treat any diarrhea. We can give medications to help with that sympathetic response in the nervous system.

Clinicians should consider a rapid taper approach for patients with cancer who exhibit repeated signs of opioid misuse, an expert said. 

Rapid Taper Plays Role in Suspected Opioid Misuse in Patients With Cancer

The new CAR-T cell therapy, anitocabtagene autoleucel (anito-cel), may offer another option beyond ciltacabtagene autoleucel (cilta-cel; Carvykti) for the treatment of patients with relapsed/refractory multiple myeloma, according to a data preview from the phase-2 iMMagine-1 trial (NCT05396885) trial released by Gilead Sciences and Arcellx.

Findings showed that per International Myeloma Working Group (IMWG) criteria, the investigator-assessed overall response rate (ORR) was 95% with a complete/stringent response rate of 62%. A total of 92% of eligible patients were minimal residual disease-negative, at least to the level of 10-5.

Kaplan-Meier-estimated 6-month progression-free survival (PFS) was 90% (95% CI, 77%-96%), and overall survival (OS) was 95% (95% CI, 85%-98%).

The median page age was 66 years, and the median follow-up was 10.3 months. Additionally, patients had received a median of 4 lines of therapy, with 45% having only 3. Of note, 69% of patients were triple-class refractory and 34% were penta-class refractory.

“Preliminary results from the first 58 patients in the phase 2 iMMagine-1 study demonstrate deep and durable responses and manageable safety in a high-risk fourth line or higher (4L+) [relapsed/refractory multiple myeloma] population including triple- and penta-class refractory disease,” the press release stated.1 “Notably, no delayed neurotoxicities, including no cranial nerve palsies, Guillain-Barré syndrome, or Parkinsonian-like symptoms have been observed with anito-cel to date.”

However, the FDA has previously placed a clinical hold on the phase 2 iMMagine-1 trial in June 2023 following a patient death that investigators attributed to limitations of the bridging therapy.

The hold was subsequently lifted in August 2023 after an investigation revealed that the death was a result of a patient who was treated with anito-cel after becoming ineligible for treatment under trial protocol before infusion with the drug and was treated in a manner that conflicted with the study’s protocol.

 The FDA approved dosing of all 17 patients enrolled in the trial prior to the partial clinical hold but had not yet been dosed before the hold, which reduced disruption of the treatment.

Following the hold lift, the FDA and the developer agreed on modifications to the trial’s protocol regarding the prevention and management of adverse effects (AEs). The FDA also permitted an expanded list of bridging options for patients enrolled in the iMMagine-1 trial to better align with current clinical practice.

In 46 patients, either no cytokine release syndrome (CRS; 16%) or grade 1 CRS (64%) was observed. For 31 patients, no fever or CRS appeared in the first 4 days of anito-cel treatment.

Regarding AEs, 3 deaths occurred due to retroperitoneal hemorrhage, CRS, and fungal infection. To date, no other therapy-related deaths or grade 3 or higher CRS/immune effector cell-associated neurotoxicity (ICAN) events have taken place. Of grade 3 or higher AEs, cytopenia was the most common treatment-emergent AE; 36 patients had neutropenia, 15 had anemia, and 15 had thrombocytopenia.

Inclusion criteria included being age 18 years or older; relapsed/refractory multiple myeloma treated with at least 3 prior regiments of systemic therapy including immunomodulatory drugs (IMiD), proteasome inhibitor, and anti-CD-38; an ECOG performance score of 0 or 1; and documented measurable disease including serum M-protein, urine M-protein, and involved serum free light chain; amongst other requirements.

Exclusion criteria were history of plasma cell leukemia; treatment with high-dose systemic steroid therapy, gene therapy, prior B-cell maturation antigen directed therapy, or autologous stem cell transplantation within 3 months to treatment; severe or uncontrolled intercurrent illness/laboratory abnormalities; and contraindication to fludarabine or cyclophosphamide; among other things.

More complete findings from the iMMagine-1 trial are to be reported at the 

2024 American Society of Hematology Annual Meeting

1. Arcellx to present clinical data for its phase 1 and iMMagine-1 studies in patients with relapsed or refractory multiple myeloma at the 66th ASH Annual Meeting and exposition and announces progress in iMMagine-3 study. News release. Arcellx, Inc. November 5, 2024. Accessed November 7, 2024. https://tinyurl.com/2u9cak8x

2. Arcellx announces clinical hold for its IMMagine-1 phase 2 clinical program. News release. Arcellx, Inc. June 19, 2023. November 7, 2024. bit.ly/3NCXBKz

3. Arcellx announces partial clinical hold lifted on IMMagine-1 phase 2 clinical program and reports second quarter financial results. News release. Arcellx. August 14, 2023. Accessed November 7, 2024. https://tinyurl.com/yd7zz2c2

Anitocabtagene autoleucel may be a promising CAR-T cell therapy option for patients with relapsed/refractory myeloma. 

Anito-Cel Shows 95% OS Rate in Relapsed/Refractory Myeloma

Patients with hormone receptor (HR)-poisitive, HER2-low or -ultralow metastatic breast cancer (MBC) who were treated with Trastuzumab deruxtecan (T-DXd; Enhertu) tended to have less deterioration in physical/role functioning and pain compared with those who were treated with a treatment of physician’s choice (TPC), according to data presented at the 2024 

European Society for Medial Oncology (ESMO) Congress

Findings were discovered via an analysis of patient-reported outcomes (PROs) on quality of life from the DESTINY-Breast06 trial (NCT04494425). Data showed a similar median time to deterioration (TTD) overall between the 2 arms in the intent-to-treat (ITT) population and the HER2-low subgroup, but differences in some symptoms. The median time to pain deterioration showed the most significant improvement for T-DXd at 22.0 months (95% CI, 17.2-not reached) vs 6.3 months (95% CI, 4.8-9.6) for TPC (HR, 0.51; 95% CI, 0.39-0.65).

“The global health/QOL was observed over 31 weeks for both arms. The QOL scores did not change from the baseline to a clinically significant degree,” Xichun Hu, MD, PhD, of the department of medical oncology in Fudan University Shanghai Cancer Center and professor in the department of oncology at Shanghai Medical College at Fudan University in Shanghai, China, said in his presentation. “Time to deterioration in QOL was similar with the 2 treatment arms. T-DXd reduced the risk of clinically meaningful deterioration in pain by 49%.”

The multicenter, open-label, randomized phase 3 DESTINY-Breast06 trial investigated the HR+, HER2-low population, defined as HER2 immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative, as well as in patients with HR+, HER2-ultralow disease, defined as HER2 IHC 0 with membrane staining. The prior lines of therapy received by patients in this study included at least 2 lines of endocrine therapy with or without targeted therapy for MBC or those who had disease progression within 6 months of starting first-line endocrine therapy and CDK4/6 inhibitor therapy for MBC or recurrence within 24 months after starting adjuvant endocrine therapy.

Patients were randomly assigned on a 1:1 basis to receive 5.4 mg/kg T-DXd every 3 weeks or TPC chemotherapy including capecitabine, nab-paclitaxel, or paclitaxel.

In the primary analysis of the trial, investigators reported that it met its primary end point of progression-free survival per blinded independent central review (BICR) assessment with T-DXd showing 13.2 months compared with 8.1 months for TPC (HR, 0.62; 95% CI, 0.51-0.74; 

The patient-reported outcomes were assessed for both the ITT population (n = 436 for T-DXd and n = 430 for TPC) and the HER2-low group (n = 359 and n = 354, respectively).1 The median duration of treatment was 11.0 months with T-DXd vs 5.6 months with TPC chemotherapy. The European Organisation for Research and Treatment of Cancer QLQ-C30 oncology-specific questionnaire and the QLQ-BR45 breast cancer­–specific questionnaire were assessed at baseline, every 3 weeks until the end of treatment, and then every 3 weeks until second progression or death.

The QLQ-C30 evaluated Global Health Status (GHS)/QOL, physical, emotional, role, social, and cognitive functional scales, and symptom scales. Hu reported that overall GHS/QOL were maintained over 31 weeks with T-DXd and TPC in the ITT population, with a mean baseline GHS score of 69.51 and 65.88, respectively. With a mean change of 10 points from baseline being considered meaningful, neither arm showed any significant shifts over time with 65.8% compliance in the T-DXd arm and 69.8% in the TPC arm. Median time to deterioration in GHS/QOL was 11.3 months (95% CI, 8.3-14.7) for T-DXd and 10.5 months (95% CI, 7.7-13.3) for TPC (HR, 0.93; 95% CI, 0.73-1.18).

In terms of pain, T-DXd significantly reduced the risk of deterioration per QLQ-C30. It also reduced risk of deterioration in several other outcomes including physical functioning (HR, 0.72; 95% CI, 0.56-0.92), role functioning (HR, 0.75; 95% CI, 0.60-0.94), emotional functioning (HR, 0.71; 95% CI, 0.53-0.95), and fatigue (HR, 0.76; 95% CI, 0.61-0.93). T-DXd was worse than TPC in nausea/vomiting (HR, 1.60; 95% CI, 1.28-2.02), appetite loss (HR, 1.33; 95% CI, 1.05-1.69), and constipation (HR, 1.74; 95% CI, 1.34-2.27).

Trastuzumab deruxtecan improved time to deterioration for pain and other categories, in patients with HER2 low/ultralow breast cancer.

Alice Kerber, MN, APRN, ACNS-BC, AOCN, APNG

Articles

Latest Updated Articles

Latest Conference Coverage